Combination of Olanzapine With Opioid-Agonists in the Treatment of Heroin-Addicted Patients Affected by Comorbid Schizophrenia Spectrum Disorders
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The objective of this study was to evaluate the efficacy of olanzapine (OLA) in heroin-dependent patients affected by comorbid schizophrenia spectrum disorders (SSD). Sixty-one patients who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for heroin dependence and the criteria for SSD (schizophrenia and schizotypal and schizoaffective-bipolar disorders) were treated in a 12-week prospective observational trial of substitution treatment in combination with OLA or typical antipsychotic haloperidol. Patients were included into 2 subgroups, in relationship with treatment, for the evaluation of the end points at week 12: group 1, SSD treated with OLA (35 patients); group 2, SSD treated with haloperidol (26 patients). Efficacy measures were retention in treatment, Symptoms Checklist-90 score changes, negative urinalyses results, and craving reduction. The rate of patients who remained in treatment at week 12 in group 1 SSD, treated with OLA, was significantly higher (32[91.4%]) than that of group 2 SSD (13 [50%]), treated with the typical antipsychotic (P < 0.001). The decrease in Symptoms Checklist-90 total scores from baseline, as expression of an improvement in comorbid psychopathology in the patients who completed the treatment, was significantly more consistent in group 1 than in group 2 patients (P < 0.01). Among the patients who remained in treatment, 64.4% achieved early full substance abuse remission, whereas 35.6% achieved partial substance abuse remission, with a significant difference between 1 (78.13%) and 2 (46.1%) treatment subgroups (P = 0.04). Although obtained by an observational-open clinical study with multiple limitations, our findings suggest that OLA may be able to increase retention and negative urinalyses rates during opioid agonist maintenance treatment in the patients with SSD and to improve psychopathology symptoms and tolerability in these dually diagnosed heroin addicts. Preliminary accurate diagnostic assessment and appropriate psychoactive medication in addicted patients affected by schizophrenia and schizotypal and schizoaffective-bipolar disorders seem to obtain less adverse effects and a more successful outcome of drug dependence treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maffei, C., Fossati, A., Agostoni, I., Barraco, A., Bagnato, M., Deborah, D., Namia, C., Novella, L., & Petrachi, M. (1997) · Journal of Personality Disorders · doi:10.1521/pedi.1997.11.3.279 · Cited by 516 · cited 2×
“All subjects received a structured interview and a diagnostic evaluation by a trained psychiatrist, using the Structural Clinical Interview for DSM-IV for Axis I disorders12 Italian version, Clinical Interview by Fava et al,13 and, according to the DSM-IV, the Structured Interview for DSM-IV Personality Disorders for…”
MethodBupropion Treatment for Cocaine Abuse and Adult Attention-Deficit/Hyperactivity Disorder
Levin, F. R., Evans, S. M., McDowell, D. M., Brooks, D. J., & Nunes, E. (2002) · Journal of Addictive Diseases · doi:10.1300/j069v21n02_01 · Cited by 102
Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study
Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., Zaimovic, A., & Lucchini, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.007 · Cited by 88
Self-citation
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“One open study in heroin-dependent patients with comorbid schizophrenia found those on olanzapine remained longer in treatment and revealed more negative urine analyses for illicit drugs compared with those on haloperidol treatment (Gerra et al., 2007) (II).”
BackgroundTorrens, M., Rossi, P. C., Martinez-Riera, R., Martinez-Sanvisens, D., & Bulbena, A. (2012) · Substance Use & Misuse · doi:10.3109/10826084.2012.663296 · Cited by 122
Sani, G., Kotzalidis, G. D., Vöhringer, P., Pucci, D., Simonetti, A., Manfredi, G., Savoja, V., Tamorri, S. M., Mazzarini, L., Pacchiarotti, I., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318287019c · Cited by 27
Danilewitz, M., & Bahji, A. (2021) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000128 · Cited by 10
Metadata
- Authors
- Gerra, G., Di Petta, G., D'Amore, A., Iannotta, P., Bardicchia, F., Falorni, F., Coacci, A., Strepparola, G., Campione, G., Lucchini, A., Vedda, G., Serio, G., Manzato, E., Antonioni, M., Bertacca, S., Moi, G., & Zaimovic, A.
- Venue
- Clinical Neuropharmacology
- Published
- 2007-05
- Volume
- 30
- Issue
- 3
- Pages
- 127-135
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2068290845
- Cited by
- 32
- References
- 3
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination of Olanzapine With Opioid-Agonists in the Treatment of Heroin-Addicted Patients Affected by Comorbid Schizophrenia Spectrum Disorders. https://app.cochat.ai/papers/10.1097/wnf.0b013e31803354f6
- The paper
- Gerra, G., Di Petta, G., D'Amore, A., Iannotta, P., Bardicchia, F., Falorni, F., Coacci, A., Strepparola, G., Campione, G., Lucchini, A., Vedda, G., Serio, G., Manzato, E., Antonioni, M., Bertacca, S., Moi, G., & Zaimovic, A. (2007). Combination of Olanzapine With Opioid-Agonists in the Treatment of Heroin-Addicted Patients Affected by Comorbid Schizophrenia Spectrum Disorders. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e31803354f6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.